MARKET

CTOR

CTOR

Citius Oncology, Inc.
NASDAQ
1.100
-0.010
-0.91%
Opening 11:48 12/05 EST
OPEN
1.100
PREV CLOSE
1.110
HIGH
1.150
LOW
1.060
VOLUME
153.41K
TURNOVER
--
52 WEEK HIGH
6.19
52 WEEK LOW
0.5506
MARKET CAP
91.86M
P/E (TTM)
-3.9823
1D
5D
1M
3M
1Y
5Y
1D
Citius Oncology Enters Exclusive Distribution Agreement With Er-Kim For Exclusive LYMPHIR Distribution Across Turkey And Key Gulf Cooperation Council Countries; Agreement Expands Citius Oncology's International Strategy To A Total Of 19 Markets Outside The U.S.
Benzinga · 1d ago
Citius Oncology expands Lymphir distribution to Turkey and Middle East
TipRanks · 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 3d ago
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years
NASDAQ · 3d ago
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma
TipRanks · 3d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 3d ago
Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment
Seeking Alpha · 3d ago
More
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Webull offers Citius Oncology Inc stock information, including NASDAQ: CTOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTOR stock methods without spending real money on the virtual paper trading platform.